INHIBITING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN
The present invention provides methods, compositions and kits for preventing, inhibiting, reducing and reversing weight gain induced by antipsychotic medications, for example olanzapine and clozapine, by co-administration of an M 1 R-selective antagonist, for example, telenzepine.
1 . A method of preventing, inhibiting, reducing or reversing weight gain in a subject receiving treatment with an antipsychotic selected from olanzapine and clozapine, comprising co-administering to the subject therapeutically effective amounts of the antipsychotic and an M 1 R-selective antagonist.
2 . The method of claim 1 , wherein the antipsychotic and the M 1 R-selective antagonist are concurrently administered.
3 . The method of claim 1 , wherein the antipsychotic and the M 1 R-selective antagonist are sequentially administered.
4 . The method of claim 1 , wherein the subject is human.
5 . The method of claim 1 , wherein delivery of at least one of the antipsychotic and the M 1 R-selective antagonist is sustained release.
6 . The method of claim 1 , wherein the M 1 R-selective antagonist is selected from the group consisting of telenzepine and pirenzepine.
7 . The method of claim 1 , wherein the M 1 R-selective antagonist is telenzepine.
8 . The method of claim 1 , wherein the antipsychotic is olanzapine.
9 . The method of claim 1 , wherein the antipsychotic is clozapine.
10 . A composition comprising a mixture of therapeutically effective amounts of an antipsychotic selected from olanzapine and clozapine and an M 1 R-selective antagonist.
11 . The composition of claim 10 , wherein the mixture is formulated for sustained release delivery of at least one of the antipsychotic and the M 1 R-selective antagonist.
12 . The composition of claim 10 , wherein the M 1 R-selective antagonist is selected from the group consisting of telenzepine and pirenzepine.
13 . The composition of claim 10 , wherein the M 1 R-selective antagonist is telenzepine.
14 . The composition of claim 10 , wherein the antipsychotic is olanzapine.
15 . The composition of claim 10 , wherein the antipsychotic is clozapine.
16 . A kit comprising a combination of therapeutically effective amounts of an antipsychotic selected from olanzapine and clozapine and an M 1 R-selective antagonist.
17 . The kit of claim 16 , wherein the antipsychotic and the M 1 R-selective antagonist are formulated in a mixture.
18 . The kit of claim 16 , wherein at least one of the antipsychotic and the M 1 R-selective antagonist are formulated for sustained release delivery.
19 . The kit of claim 16 , wherein the M 1 R-selective antagonist is selected from the group consisting of telenzepine and pirenzepine.
20 . The kit of claim 16 , wherein the M 1 R-selective antagonist is telenzepine.
21 . The kit of claim 16 , wherein the antipsychotic is olanzapine.
22 . The kit of claim 16 , wherein the antipsychotic is clozapine.